Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Chorion Villus Biopsy Needle Set market was valued at USD 34.9 million in 2024 and is projected to reach USD 44.9 million by 2031, exhibiting a CAGR of 3.8% during the forecast period. The primary drivers for this market include the increasing prevalence of genetic disorders, advancements in prenatal diagnostics, and growing awareness about early detection methods. However, market growth is tempered by the invasive nature of the procedure and associated risks.
Chorionic villus sampling (CVS) is a prenatal test performed between weeks 10 and 13 of pregnancy to detect chromosomal abnormalities and genetic disorders. The needle set is designed for transabdominal collection of chorionic villi samples under ultrasound guidance. Key manufacturers are focusing on developing safety-enhanced designs with features like echogenic tips for better ultrasound visibility and depth markers for precise insertion.
The market is segmented by needle gauge, with 18G being the most commonly used size (holding approximately 60% market share in 2024) due to optimal balance between sample quality and patient safety. Geographically, North America leads in adoption rates due to advanced healthcare infrastructure and higher incidence of prenatal testing, followed by Europe with its strong regulatory framework ensuring device safety and efficacy.
Recent industry developments include the July 2023 FDA clearance of an enhanced CVS needle set with integrated pressure monitoring, reducing complication risks. Major players include Medtronic, Cook Medical, and Cardinal Health, who are expanding their product portfolios through both organic development and strategic acquisitions of smaller specialized manufacturers.
Rising Demand for Prenatal Diagnostics
The increasing prevalence of genetic disorders and chromosomal abnormalities has driven demand for advanced prenatal testing methods. Chorion villus biopsy remains a critical diagnostic tool, with growing adoption in both developed and emerging healthcare markets.
Expansion of Advanced Healthcare Infrastructure
Hospitals and diagnostic centers are investing in state-of-the-art equipment for prenatal care, including specialized needle sets for chorionic villus sampling. The global push toward personalized medicine has increased demand for precise genetic testing tools.
➤ Hospitals performed over 1.2 million prenatal diagnostic procedures globally in 2023, with 35% requiring specialized biopsy equipment
Governments and private healthcare providers are increasing budgets for maternal and child health programs, creating sustainable demand for CVS equipment and related medical devices.
MARKET CHALLENGES
High Cost of Specialized Equipment
The development and manufacturing of specialized, single-use CVS needle sets requires significant R&D investment and specialized manufacturing capabilities. This creates barriers to entry for new market entrants and limits competition in some regions.
Other Challenges
Regulatory Hurdles Across Regions
Different countries have varying regulatory requirements for medical devices, particularly those used in invasive procedures. The approval process for CVS needle sets can take 12-18 months in some markets, delaying market entry.
Limited Skilled Practitioners
CVS procedures require highly trained maternal-fetal medicine specialists and genetic counselors. The global shortage of these specialists, particularly in developing regions, limits procedure volume and thus demand for specialized needle sets.
Emerging Markets Expansion
Developing countries with improving healthcare infrastructure present significant growth opportunities. As prenatal care becomes more accessible in regions like Southeast Asia and Africa, demand for advanced diagnostic tools including CVS equipment will increase substantially.
The global CVS market is projected to reach $350 million by 2028, with compound annual growth of 7.2%. This growth will be driven by increasing genetic disorder screening, higher maternal age in developed countries, and technological improvements in biopsy techniques.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Disposable Needle Sets dominate due to their sterility assurance and reduced cross-contamination risk, which is absolutely critical in prenatal diagnostic procedures where patient safety and procedural integrity are paramount considerations. |
| By Application |
|
Prenatal Diagnosis Centers demonstrate strongest adoption due to their specialized focus on chromosomal abnormality detection and high procedure volumes, supported by comprehensive genetic counseling infrastructure and established referral networks from obstetric care providers. |
| By End User |
|
Specialty Clinics exhibit the highest utilization rates owing to their focused service offerings in maternal-fetal medicine, where specialized practitioners require optimized instrumentation for precise villus sampling with minimal tissue trauma and maximum sample integrity for accurate genetic analysis. |
Companies Invest in Advanced Technologies to Enhance Market Position
Cook Medical (USA) maintains its leadership position through its comprehensive portfolio of specialized biopsy needles and global distribution network, securing approximately 25% market share in the chorion villus biopsy segment.
Medtronic plc (Ireland) and B. Braun Melsungen AG (Germany) follow closely with strong European market presence, offering specialized biopsy devices with enhanced safety features and ergonomic designs that appeal to obstetricians and gynecologists.
Rocket Medical plc (UK) has significantly expanded its market reach through strategic partnerships with major hospital networks, while Integra LifeSciences (USA) focuses on R&D investments for next-generation biopsy systems with integrated imaging compatibility.
Emerging players including Cardinal Health (USA) and Terumo Corporation (Japan) are expanding their product portfolios through acquisitions and regional distribution partnerships, particularly targeting growth markets in Asia-Pacific and Latin America.
List of Key Chorion Villus Biopsy Needle Set CompaniesCook Medical (USA)
Medtronic plc (Ireland)
B. Braun Melsungen AG (Germany)
Rocket Medical plc (UK)
Integra LifeSciences (USA)
Cardinal Health (USA)
Terumo Corporation (Japan)
The global chorion villus biopsy needle set market is experiencing significant growth due to rising demand for early and accurate prenatal diagnosis. Healthcare providers are increasingly adopting these specialized instruments to perform chorionic villus sampling (CVS) procedures with higher precision and reduced risk. Market analysis indicates a 12.3% year-over-year growth in procedural volumes, particularly in North America and Europe where advanced prenatal care standards are implemented.
Other TrendsTechnological Advancements in Needle Design
Manufacturers are focusing on developing next-generation CVS needles with improved echogenicity for better ultrasound guidance and reduced outer diameters for minimized tissue trauma. The latest iterations feature hydrophilic coatings that reduce friction during insertion and specialized tip geometries that allow for cleaner tissue collection. These innovations are driving adoption even in price-sensitive markets as healthcare systems recognize the long-term cost benefits of accurate prenatal diagnosis.
While North America and Europe continue to hold significant market shares, emerging economies in Asia-Pacific and Latin America are showing accelerated growth rates. Increasing healthcare expenditure, rising awareness about prenatal care, and improving healthcare infrastructure are contributing to market expansion. International manufacturers are establishing distribution partnerships with local healthcare suppliers to improve accessibility to quality-controlled CVS instruments, with several countries reporting 15-20% annual growth in CVS procedure volumes.
Market analysis indicates the global chorion villus biopsy needle set market will maintain strong growth through 2030, driven by increasing maternal age, rising prevalence of genetic disorders, and advancements in prenatal diagnostic technologies. Manufacturers continue to invest in R&D to develop safer, more efficient instruments that meet evolving clinical requirements.
Regional Analysis: Chorion Villus Biopsy Needle Set MarketEurope
European markets maintain strong demand through integrated healthcare systems that emphasize preventive care. Countries with advanced healthcare systems like Germany and the UK have established comprehensive prenatal screening programs that utilize specialized equipment. The region benefits from cross-border collaboration in medical research and standardized training programs for medical professionals. European manufacturers have developed expertise in producing high-precision medical devices that meet stringent EU regulatory requirements while maintaining cost-effectiveness.
Asia-Pacific
The Asia-Pacific region demonstrates the fastest growth rate due to rapidly developing healthcare infrastructure and increasing government focus on maternal health. Countries like Japan and South Korea have world-class medical research institutions that contribute to device development. Australia and New Zealand maintain high standards of care that drive demand for quality medical devices. The region benefits from growing medical tourism and knowledge exchange with Western markets, accelerating adoption of advanced medical technologies.
Latin America
Latin American markets show consistent growth supported by improving economic conditions and healthcare reforms. Countries like Brazil and Argentina have developed specialized maternal care centers that utilize advanced diagnostic equipment. The region benefits from proximity to North American markets, facilitating knowledge transfer and equipment standardization. Healthcare policies increasingly emphasize preventive care, creating sustained demand for specialized medical devices across the region.
Middle East & Africa
While development varies across this diverse region, significant progress has been made in modernizing healthcare infrastructure. Wealthier Middle Eastern nations have established specialized medical centers that utilize advanced diagnostic equipment. African nations are gradually expanding access to specialized care through international partnerships and infrastructure development. The region represents significant future potential as economic development continues to improve healthcare access and quality across diverse markets.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2031. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Chorion Villus Biopsy Needle Set market was valued at USD 34.9 million in 2024 and is projected to reach USD 44.9 million by 2031.
-> The market is expected to grow at a CAGR of 3.8% during the forecast period 2024-2031.
-> Key manufacturers include Cook Medical, STERYLAB, Biopsybell, and Rocket Medical.
-> Major types include Diameter 17G, Diameter 18G, and others, with 18G holding approximately 60% market share.
-> North America leads in adoption rates due to advanced healthcare infrastructure.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates